A Randomized Double-Blind Parallel-Group Comparative Phase 2 Study to Evaluate the Immunogenicity and Safety of a Single Subcutaneous Injection of TAK-850 in Comparison With Influenza HA Vaccine in Healthy Adult Subjects
Latest Information Update: 07 Jan 2022
At a glance
- Drugs TAK 850 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Takeda
Most Recent Events
- 23 Sep 2015 New trial record